Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Outlook Therapeutics Inc (NASDAQ: OTLK) closed at $1.61 up 0.62% from its previous closing price of $1.60. In other words, the price has increased by $0.62 from its previous closing price. On the day, 0.76 million shares were traded.
Ratios:
For a deeper understanding of Outlook Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.57 and its Current Ratio is at 0.72.
On March 27, 2024, BTIG Research Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $50.
Chardan Capital Markets Upgraded its Neutral to Buy on February 15, 2024, while the target price for the stock was maintained at $3.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’24 when KENYON LAWRENCE A bought 5,000 shares for $5.69 per share. The transaction valued at 28,446 led to the insider holds 5,946 shares of the business.
Stock Price History:
Over the past 52 weeks, OTLK has reached a high of $9.25, while it has fallen to a 52-week low of $0.87. The 50-Day Moving Average of the stock is 9.32%, while the 200-Day Moving Average is calculated to be -52.76%.
Shares Statistics:
A total of 32.91M shares are outstanding, with a floating share count of 21.11M. Insiders hold about 37.11% of the company’s shares, while institutions hold 21.30% stake in the company.
Earnings Estimates
Its stock is currently analyzed by 3.0 different market analysts. The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.13 and low estimates of -$0.51.
Analysts are recommending an EPS of between -$1.4 and -$2.52 for the fiscal current year, implying an average EPS of -$2.08. EPS for the following year is -$1.29, with 3.0 analysts recommending between -$0.95 and -$1.77.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $6.76M. There is a high estimate of $8.7M for the next quarter, whereas the lowest estimate is $4M.
Based on 5 analysts’ estimates, the company’s revenue will be $34.93M in the next fiscal year. The high estimate is $50.95M and the low estimate is $17.1M.
